| Literature DB >> 36071404 |
A A van Driel1, M Mulder2,3, E E Stobberingh3,4, A Verbon5.
Abstract
BACKGROUND: To optimize antibiotic treatment and decrease antibiotic resistance, national treatment guidelines are available for urinary tract infections (UTIs) in general practice. The usefulness of these guidelines in risk areas for antimicrobial resistance such as cross border regions or areas with dense agriculture, is unknown.Entities:
Keywords: Agriculture; Antibiotic resistance; Community-acquired; Empirical prescription; Treatment guidelines; Uncomplicated urine tract infections
Mesh:
Substances:
Year: 2022 PMID: 36071404 PMCID: PMC9450366 DOI: 10.1186/s12875-022-01840-6
Source DB: PubMed Journal: BMC Prim Care ISSN: 2731-4553
Fig. 1Inclusion of patients with symptoms of an UTI. Figure 1 shows the inclusion of patients presenting with UTI symptoms in 8 GP’s in the Westland and whether empirical antibiotics (AB) were prescribed. Two patients were excluded due to an incomplete questionnaire (n = 2). The diagnosis of UTI was confirmed by laboratory culture analyses after clinical presentation and diagnoses of the GP
Patients characteristics
| 11–20 | 23 (7.4) | 18 (7.3) | 5 (7.9) |
| 21–50 | 100 (32.3) | 77 (31.2) | 23 (36.5) |
| 51–70 | 115 (37.1) | 96 (38.9) | 19 (30.2) |
| ≥ 71 | 72 (23.2) | 56 (22.7) | 16 (25.4) |
| Pain/burning sensation | 236 (76.1) | 192 (77.7) | 44 (69.9) |
| Polyuria | 155 (50.0) | 127 (51.4) | 28 (44.4) |
| Urinary urgency | 57 (18.4) | 48 (19.4) | 9 (14.3) |
| Haematuria | 38 (12.3) | 33 (13.4) | 5 (7.9) |
| Flank pain | 58 (18.7) | 47 (19.0) | 11 (17.5) |
| 174 (56.1) | 139 (56.3) | 35 (55.6) | |
| 183 (59.0) | 146 (59.1) | 37 (58.7) | |
| Amoxicillin | 18 (5.8) | 12 (4.8) | 6 (9.5) |
| Co-amoxiclav | 6 (1.9) | 4 (1.6) | 2 (3.2) |
| Doxycycline | 10 (3.2) | 10 (4.0) | 0 (0.0) |
| Nitrofurantoin | 131 (42.3) | 104 (42.0) | 27 (42.9) |
| Fosfomycin | 42 (13.5) | 34 (13.8) | 8 (12.7) |
| Trimethoprim | 16 (5.2) | 15 (6.1) | 1 (1.6) |
| Ciprofloxacin | 21 (6.8) | 16 (6.5) | 5 (7.9) |
| Norfloxacin | 6 (1.9) | 6 (2.4) | 0 (0.0) |
| Co-trimoxazole | 2 (0.6) | 2 (0.8) | 0 (0.0) |
| Clarithromycin | 1 (0.3) | 1 (0.4) | 0 (0.0) |
| Flucloxacillin | 4 (1.3) | 3 (1.2) | 1 (1.6) |
| Azithromycin | 2 (0.6) | 1 (0.4) | 1 (1.6) |
| Cefuroxime | 1 (0.3) | 1 (0.4) | 0 (0.0) |
| Metronidazole | 1 (0.3) | 0 (0.0) | 1 (1.6) |
| 53 (17.1) | 45 (18.3) | 8 (12.7) | |
| Within Europe | 37 (11.9) | 31 (12.6) | 6 (9.5) |
| Outside Europe | 16 (5.2) | 14 (5.7) | 2 (3.2) |
| 148 (47.7) | 128 (51.8) | 20 (31.7) | |
| Amoxicillin | 1 (0.3) | 1 (0.4) | 0 (0.0) |
| Co-amoxiclav | 1 (0.3) | 0 (0.0) | 1 (1.6) |
| Nitrofurantoin | 112 (36.1) | 97 (39.3) | 15 (23.8) |
| Fosfomycin | 19 (6.1) | 16 (6.5) | 3 (4.7) |
| Trimethoprim | 9 (2.9) | 8 (3.2) | 1 (1.6) |
| Ciprofloxacin | 5 (1.6) | 5 (2.0) | 0 (0.0) |
| Norfloxacin | 1 (0.3) | 1 (0.4) | 0 (0.0) |
| none | 162 (52.3) | 119 (48.2) | 43 (68.3) |
Table 1 shows the patient characteristics of the study. The first column (total) shows the characteristics of all patients included in the study, Table 1 the second column (UTI) the characteristics of the patients with a culture confirmed UTI and the third column the characteristics of the patients without a culture confirmed UTI
Factors associated with empirical antibiotic prescribing of patients visiting the GP for complaints of an UTI
| OR (95% CI) | |
|---|---|
| 1.01 (0.99–1.02) | |
| 0.42 (0.12–1.51) | |
| No or 1 symptom | Ref |
| 2 symptoms | 2.50 (1.46–4.29)* |
| 3 or more symptoms | 4.07 (2.07- 8.01)* |
| 1.98 (1.06–3.69)* | |
| 1.74 (0.48–6.24) | |
| No | Ref |
| Yes, Europe | 0.85 (0.41–1.78) |
| Yes, outside Europe | 0.51 (0.16–1.57) |
Table 2 shows the associated factors of empirical antibiotic prescription of patients visiting the GP with complaints of an UTI. Associated factors are age; the number of symptoms patients were suffering from; a culture proven UTI; antibiotic use in the year before this study and traveling abroad in the last 12 months. * Significant with p < 0.05
Fig. 2Percentages of antibiotic resistance of E. coli of the Westland (2018), NIVEL 2004, 2009, and 2014. Figure 2 shows the AMR percentage of the Westland in comparison to the NIVEL study of 2004, 2009 and 2014 [27–30]. Also the percentage of ESBL is shown